



SICGEN ANTIBODIES

BEST ANTIBODY DEVELOPMENT & PRODUCTION COMPANY - PORTUGAL

SICGEN Antibodies is a developer, manufacturer, and marketer of polyclonal antibodies used in cell biology research. The company was founded in 2008 as a spin-off from the University of Coimbra by José Ramalho, a Portuguese scientist who is also a researcher at the NOVA University of Lisbon.

Situated in a small village in the Coimbra district, the company's Production Unit includes a laboratory and an animal house, producing hundreds of goat antibodies annually.

SICGEN Antibodies (SICGEN) specializes in the development, production, and marketing of innovative antibodies that have proven successful across various life science research areas. Notably, antibodies targeting fluorescent proteins like GFP, mCherry, and tdTomato have been prominently featured in esteemed research publications such as Nature, Cell, and Science. As of 2023, SICGEN boasts a product line comprising over 300 items, primarily employed for research purposes in Western Blotting (WB), Immunofluorescence (IF), and Immunocytochemistry (IHC).

While many of these antibodies are already utilized in techniques such as ELISA and immunoprecipitation, SICGEN is dedicated to ongoing innovation.

The company continually strives to develop new antibody-related products to advance research, catering to leading institutions globally, including universities, research centers, pharmaceutical manufacturers, and biotechnology distributors. SICGEN specializes particularly in the North American, European, and Far East markets.

The company's success is attributed to its focus on niche areas with clear gaps in the supply of high-quality antibodies. Stemming from its academic origins and with scientist founders, SICGEN easily identified and focused on producing antibodies in high demand.

Anticipating key scientific trends has given the company a competitive edge, and embracing cutting-edge technologies for increased and improved antibody production remains a priority.

José believes that SICGEN's commitment to innovation will propel it to become a global leader in polyclonal antibody production, offering top-tier service and competitive prices.


Research and development in the antibody industry are vital for advancing scientific research by providing tools that enable the study of processes and molecules.



To manage increasing demand, SICGEN evolves by enhancing antibody quality, specificity, and reproducibility. Collaborating with researchers, industry professionals, and regulatory bodies ensures continuous advancement in meeting the scientific community's needs. Challenges faced by the industry, such as antibody cost and ensuring reproducibility and specificity, have led SICGEN to implement guidelines and standards, emphasizing antibody validation.

To manage costs without compromising quality, SICGEN explores strategies, such as attaining goat antibodies to streamline manufacturing processes and improve scalability. The company upholds rigorous antibody validation protocols through transparent recording of validation data, building trust with researchers and differentiating itself from competitors lacking innovation.

Looking ahead, SICGEN remains focused on developing, producing, and marketing new antibodies to address market gaps. Plans include expanding into new markets, increasing distributor channels, and implementing a sample program. Leveraging the latest technological developments will provide opportunities for innovation, aligning with the company's goal of becoming the premier global producer of polyclonal antibodies.



Contact Details

Contact: José Ramalho

Company: SICGEN Antibodies

Web Address: www.sicgen.pt